Patents Represented by Attorney Richard W. Boak, Esq.
  • Patent number: 6875760
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: April 5, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Inge Thøger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thøgersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jøgensen, Janos Tibor Kodra, Shenghua Shi
  • Patent number: 6706744
    Abstract: Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: March 16, 2004
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Jesper Lau, Anthony Ling
  • Patent number: 6653492
    Abstract: Certain bile acids find use in the pharmaceutical industry. In view of the wide distribution of serious diseases such as HIV, AIDS and Bovine Spongiform Encephalopathy (BSE) it is desirable to avoid—as far as practicable—to have any components of animal origin in medicaments in order to eliminate any danger of infection. The present invention relates to a method of providing bile acids from non-animal starting materials.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: November 25, 2003
    Assignee: Novo Nordick A/S
    Inventor: Peter Faarup